APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
NCT00343460
Completed
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/10/2017
Locations: Star Hematology & Oncology, Phillipsburg, New Jersey
Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Phase 2 Trial of Bevacizumab in Combination With Pemetrexed
NCT00227019
Completed
This trial evaluated the safety of combining bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) patients with stable brain metastases as second-line chemotherapy, while evaluating progression-free survival (PFS) and overall survival (OS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2017
Locations: Cooper Cancer Institute, Voorhees, New Jersey
Conditions: Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Register for Updates
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
NCT02069093
Completed
Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/20/2016
Locations: Regional Cancer Care Associates Cancer and Hematologic Disease, Cherry Hill, New Jersey +1 locations
Conditions: Advanced Breast Cancer
Register for Updates
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01029054
Completed
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2016
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
NCT02150213
Completed
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2016
Locations: Novartis Investigative Site, Monroe Township, New Jersey
Conditions: Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Register for Updates
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
NCT00884546
Completed
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/28/2016
Locations: John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Advanced Cancer, Various, NOS
Register for Updates
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
NCT00002676
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells and may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and whole-brain radiation therapy in patients with primary central nervous system non-Hodgkin's lymph... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2016
Locations: CCOP - Northern New Jersey, Hackensack, New Jersey
Conditions: Lymphoma
Register for Updates
An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)
NCT02188173
Completed
This is a study of OZURDEX® use in clinical practice in patients with diabetic macular edema (DME).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/31/2016
Locations: New Jersey Retina, New Brunswick, New Jersey
Conditions: Macular Edema
Register for Updates
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
NCT01204164
Completed
This is a multicenter, open-label, dose escalation Phase 1 study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2016
Locations: HUMC, Hackensack, New Jersey
Conditions: AML, ALL, Blast Crisis, MDS, Multiple Myeloma
Register for Updates
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
NCT00532155
Completed
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC). The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunog... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/04/2016
Locations: Sanofi-Aventis Administrative Office, Bridgewater, New Jersey
Conditions: Carcinoma, Non Small Cell Lung
Register for Updates
MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma
NCT00833833
Completed
The purpose of this study is to determine the maximum tolerated dose and effectiveness of the study drug (CC-4047) Alone Or in Combination With Low-dose Dexamethasone as treatment for patients with relapsed and refractory multiple myeloma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2016
Locations: The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus
NCT00007358
Completed
Some newborns are born with congenital heart block (CHB), a condition occurring in babies with neonatal lupus. The first part of the study will test the effectiveness of fluorinated steroids, including dexamethasone, in improving the heart function and general health of newborns who have auto-antibody-associated CHB. The second part of this study will use ultrasound and heart monitoring to observe high-risk pregnant women and their fetuses during the third trimester of pregnancy.
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
03/10/2016
Locations: St. Barnabas Medical Center, Livingston, New Jersey
Conditions: Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury
Register for Updates